Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

8354 source entries across 8152 studies. This list may not include all unresolved or historical entries.

Success Metrics

Clinical Success Rate
87.4%

Based on 26,997 completed trials

Completion Rate
87%(26997/30886)
Active Trials
4,811(11%)
Results Posted
48%(12843 trials)
Terminated
3,889(9%)

Phase Distribution

Phase 1/2
1,584
4%
Phase 3
8,993
21%
Phase 2
11,490
27%
Not Applicable
6,976
17%
Phase 4
4,178
10%
Phase 2/3
1,493
4%
Early Phase 1
575
1%
Phase 1
6,664
16%

Phase Distribution

7239

Early Stage

14567

Mid Stage

13171

Late Stage

Phase Distribution41953 total trials
Early Phase 1First-in-human
575(1.4%)
Phase 1Safety & dosage
6,664(15.9%)
Phase 1/2Combined phases
1,584(3.8%)
Phase 2Efficacy & side effects
11,490(27.4%)
Phase 2/3Combined phases
1,493(3.6%)
Phase 3Large-scale testing
8,993(21.4%)
Phase 4Post-market surveillance
4,178(10.0%)
N/ANon-phased studies
6,976(16.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.6%

26997 of 32277 finished

Non-Completion Rate

16.4%

5280 ended early

Currently Active

4700

trials recruiting

Total Trials

42,055

all time

Status Distribution
Active(6119)
Completed(26997)
Terminated(5280)
Other(3659)

Detailed Status

Completed26997
Terminated3889
unknown3548
Recruiting3291
Active, not recruiting1409
Withdrawn1391

Development Timeline

Analytics

Development Status

Total Trials
42055
Active
4811
Success Rate
87.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 1575 (1.4%)
Phase 16664 (15.9%)
Phase 1/21584 (3.8%)
Phase 211490 (27.4%)
Phase 2/31493 (3.6%)
Phase 38993 (21.4%)
Phase 44178 (10.0%)
N/A6976 (16.6%)

Trials by Status

completed2699764%
withdrawn13913%
enrolling_by_invitation1110%
terminated38899%
not_yet_recruiting13083%
unknown35488%
recruiting32918%
active_not_recruiting14093%
suspended1110%

Recent Activity

Clinical Trials (42,055)

Showing 20 of 42,055 trialsScroll for more
NCT01712620Phase 2

Spironolactone for Pulmonary Arterial Hypertension

Recruiting
NCT04210115Phase 3

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Completed
NCT04522739Phase 4

Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia

Completed
NCT04666610Phase 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Completed
NCT04675151Phase 2

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

Completed
NCT04692688Phase 2

Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy

Completed
NCT04744883Early Phase 1

Efficacy of Spinal Manipulation Therapy or Mindfulness-based Reduction Therapy on Patients With Chronic Low Back Pain

Completed
NCT05135702Not Applicable

Effect of Propionic Acid Supplementation on Endothelial Function

Not Yet Recruiting
NCT05410925Phase 4

Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction

Recruiting
NCT05583227Phase 3

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

Active Not Recruiting
NCT05614115Phase 1

Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

Completed
NCT05624450Phase 3

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Recruiting
NCT05636293Phase 2

Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission

Completed
NCT05646719Phase 3

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

Completed
NCT05648500Phase 3

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Active Not Recruiting
NCT05672576Phase 3

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

Active Not Recruiting
NCT05713799Phase 2

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

Not Yet Recruiting
NCT05809908Phase 3

Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study

Not Yet Recruiting
NCT05928936Phase 2

Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD

Recruiting
NCT06030804Not Applicable

Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery

Recruiting

Drug Details

Intervention Type
Varies by study
Total Trials
42,055